Clinical Analysis Of TAC Regimen As Adjuvant Chemotherapy In The Treatment Of Breast Cancer Patients

Objective：Analyse and summarize the clinical features,efficiency,adverse effectsof breast cancer patients who were accepted TAC regimen as adjuvant chemotherapyin Jilin University No.1Hospital between march2007and may2009.Methods: Collected the clinical data of the146breast cancer patients throughlooking up medical records and follow-up,calculated3-year DFS and3-year OS, drewthe survival curve, adopted Kaplan-meier method and Cox proportion hazard model toanalyse the influence of clinicopathological factors to the prognosis of breast cancerpetients,and evaluated the adverse effects of TAC regimen as adjuvant chemotherapyfor breast cancer patiens.Results: The follow-up time was5-63months,follow-up rate was89.7%.Localrelapse and distant metastasis occurred in24patients(18.3%) between5-51monthsafter operation,11patients(8.4%) died from breast cancer between5-57months afteroperation,2patients(1.5%) died from other diseases.The3-year DFS was81.7%and3-year OS was93.1%. There were significant differences of3-year DFS in diffrtentlymph node status and different pathological stage.There were also significantdifferences of3-year DFS and3-year OS in diffrtent vascular invasion status. Therewere no significant differences of3-year DFS and3-year OS in other groupingmethods.Factors affecting the3-year DFS were vascular invasion,number of lymphnode metastasis,pathological stage by univariate analysis;factors not affecting the3-year DFS were age,menopausal,histological types,ER expression,PRexpression,Her-2expression,tumer size,risk layer by univariate analysis.There were nosignificant differences of3-year OS in different clinicopathological factors.Thevascular invasion was significant independent indicators of prognosis bymultivariate analysis.The main side effects of TAC regimen were bone marrowsuppression and gastrointestinal effects.The incidence of leucopenia was84.7%,neutropenia was50.4%,thrombocytopenia was9.2%, decreasedhemoglobin was42.0%, febrile neutropenia(NF) was16.0%,nausea and vomit was79.4%.The difference in grade III-IV leucopenia and NF rate between patientsyounger than50years and aged50years or older was significant. The difference in leucopenia,NF, nausea and vomit,peripheral neuropathy rate between patientswho had complications and patients who had no complications was nosignificant.Conclusions: TAC is an effective regimen as a standard adjuvant chemotherapyregimen for breast cancer patients.The3-year DFS of the breast cancer patients whowere accepted TAC regimen as adjuvant chemotherapy was related with vascularinvasion,number of lymph node metastasis and pathological stage; The3-year DFSwas not related with age,menopausal,histological types,ER expression,PRexpression,Her-2expression,tumer size,risk layer.Vascular invasion is an independentprognostic factor influencing3-year DFS of breast cancer patients.The3-year OS ofthe breast cancer patients who were accepted TAC regimen as adjuvant chemotherapywas not related with clinicopathological factors. The main adverse effects of TACregimen as adjuvant chemotherapy were bone marrow suppression and gastrointestinaleffects,all of them were reversible and well-tolerated.No chemotherapy related deathshappened.The tolerance was related with age and was not related with complications.